◆英語タイトル:AGILeBiotics BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11130
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
AGILeBiotics BV (AGILeBiotics) is a pharmaceutical company that focus on the discovery and development of new antibiotics to treat multi-drug resistant infections. The company’s patented synthetic method technology OxaSelect transforms the currently available antibiotics, which became less effective owing to bacterial resistance, into new antibiotic derivatives that surmount bacterial resistance to treat severe infections caused by multi-drug resistant (MDR) bacteria. It works in collaboration with The University Medical Center Groningen, The University Hospital Muenster, The Hopsital Olderburg, Integrex Research, and Syncom BV, to design and develop novel antibiotic candidates. AGILeBiotics is a spin-off of the University of Groningen. The company operates in the Netherlands. AGILeBiotics is headquartered in Groningen, the Netherlands.
AGILeBiotics BV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AGILeBiotics BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
AGILeBiotics Raises Funds through Pre-Seed Financing 10
Partnerships 11
AGILeBiotics Enters into Agreement with Syncom 11
Equity Offering 12
AGILeBiotics Spin-Off from University of Groningen 12
AGILeBiotics BV – Key Competitors 13
AGILeBiotics BV – Key Employees 14
AGILeBiotics BV – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Strategy And Business Planning 16
Apr 10, 2017: AGILeBiotics joins the Health-i-Care program 16
Corporate Communications 17
Jun 01, 2017: AGILeBiotics Appoints Dr. Maria Bastian as CSO 17
Government and Public Interest 18
Feb 01, 2017: AGILeBiotics receives the Take-off fase one grant from NWO 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19
List of Tables
AGILeBiotics BV, Pharmaceuticals & Healthcare, Key Facts 2
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AGILeBiotics BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AGILeBiotics BV, Deals By Therapy Area, 2012 to YTD 2018 8
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AGILeBiotics Raises Funds through Pre-Seed Financing 10
AGILeBiotics Enters into Agreement with Syncom 11
AGILeBiotics Spin-Off from University of Groningen 12
AGILeBiotics BV, Key Competitors 13
AGILeBiotics BV, Key Employees 14
List of Figures
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8